Genmab A/S is an international biotechnology company focused on antibody therapeutics for cancer and other serious diseases.
Last price · Nov 10, 2026, 15:59 (UTC)
1Y change
Since the Nov 11, 2025 close
GMAB.CO · 1Y · DKK · 248 observations (daily) (details)
Nov 11, 2025 — Nov 10, 2026. First close: kr 1,919.00. Latest price: kr 3,581.00.
Show last 20 observations in a table
| Date | Price (DKK) |
|---|---|
| Oct 14, 2026 | kr 2,481.00 |
| Oct 15, 2026 | kr 2,529.00 |
| Oct 16, 2026 | kr 2,502.00 |
| Oct 19, 2026 | kr 2,542.00 |
| Oct 20, 2026 | kr 2,602.00 |
| Oct 21, 2026 | kr 2,620.00 |
| Oct 22, 2026 | kr 2,654.00 |
| Oct 23, 2026 | kr 2,644.00 |
| Oct 26, 2026 | kr 2,964.00 |
| Oct 27, 2026 | kr 2,997.00 |
| Oct 28, 2026 | kr 3,868.00 |
| Oct 29, 2026 | kr 3,788.00 |
| Oct 30, 2026 | kr 3,912.00 |
| Nov 2, 2026 | kr 3,698.00 |
| Nov 3, 2026 | kr 3,719.00 |
| Nov 4, 2026 | kr 3,578.00 |
| Nov 5, 2026 | kr 3,635.00 |
| Nov 6, 2026 | kr 3,527.00 |
| Nov 9, 2026 | kr 3,661.00 |
| Nov 10, 2026 | kr 3,581.00 |
Key statistics
From observed daily candles · based on settled daily closes
- 52-week range
- kr 1,512.00 – kr 3,947.00
Low Jun 3, 2026 · High Oct 30, 2026
- 1Y change
- +86.61%
Since the Nov 11, 2025 close
- Last close
- kr 3,581.00
Nov 10, 2026 · −2.19%
- Previous close
- kr 3,661.00
Nov 9, 2026
- Day range
- kr 3,581.00 – kr 3,728.00
Nov 10, 2026
Product information
What is Genmab A/S (GMAB.CO)?
Genmab A/S is an international biotechnology company focused on antibody therapeutics for cancer and other serious diseases. It was established in 1999, is headquartered in Copenhagen and has a presence in North America, Europe and Asia Pacific.
Genmab receives royalties from Johnson & Johnson on worldwide sales of DARZALEX, and Kesimpta is marketed by Novartis under a licence from Genmab. EPKINLY (epcoritamab) and Tivdak, developed with Pfizer, are also among the company's products. Genmab completed its tender offer for the Dutch biotechnology company Merus in December 2025, adding Merus's antibody candidate petosemtamab to its pipeline. Genmab's ordinary shares trade on Nasdaq Copenhagen under the code GMAB, and its American depositary shares (ADSs) began trading on the Nasdaq Global Select Market in the United States under the same code in 2019.
Those following Genmab stock usually watch the sales development of the medicines that generate royalties, clinical trial results, approval processes and partnership announcements. On the Lzzo.com Genmab page, the price of the Copenhagen-listed shares appears with its observation time, together with a price history chart and technical indicators.
Sources: genmab.com, ir.genmab.com
Author: Lzzo Editor · Prepared with AI assistance and reviewed by the Lzzo.com editorial team · Editorial policy
- Name
- Genmab A/S
- Symbol
- GMAB.CO
- Market
- Stocks
Not investment advice · Data and calculation methods
Technical indicators
Data-based commentary (AI)
Not investment advice. Analysis unit: DKK.
Investment Return CalculatorWith observed closes over the past year
Observed closes in the selected currency; excludes dividends and fees. Based on settled daily closes.
Nov 11, 2025 → Nov 10, 2026
kr 1,866.08
kr 1,000.00 held from the Nov 11, 2025 close to the Nov 10, 2026 close would have been worth kr 1,866.08 (+86.61%).